Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease
Open accessAbstract
Nephrology Dialysis Transplantation, gfx350, https://doi.org/10.1093/ndt/gfx350 In the above article, the n numbers for the least squares mean values (LSM) reported below figure 2A were incorrect. The numbers for Week 102 were repeated under the graph rather than displaying the true LSM values, which were 62 for placebo, 55 for dapagliflozin 5 mg and 85 for dapagliflozin 10 mg. The authors apologise for the error which has been corrected.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Cardiovascular and kidney events are reduced with SGLT2 inhibitor use in individuals with severe CKD independent of glucose-lowering effects.
“Cardiovascular and kidney events are reduced with SGLT2 inhibitor use in individuals with severe CKD independent of glucose-lowering effects (126,131).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [131]
Cited by
Sorted by citations
Dekkers, C. C. J., Sjöström, C. D., Greasley, P. J., Cain, V., Boulton, D. W., & Heerspink, H. J. L. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13855 · Cited by 106 · see citing works
Self-citation11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s011 · Cited by 108 · see citing works
- Authors
- Dekkers, C. C. J., Wheeler, D. C., Sjöström, C. D., Stefansson, B. V., Cain, V., & Heerspink, H. J. L.
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-05-11
- Volume
- 33
- Issue
- 7
- Pages
- 1280-1280
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- PMC
- PMC6031052
- OpenAlex
- W4252551836
- Cited by
- 22
- References
- 0
- Citations by year
- 2025: 1 · 2023: 1 · 2022: 4 · 2021: 2 · 2020: 4 · 2019: 4 · 2018: 6
- FWCI
- 3.18
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Nephrology Dialysis Transplantation (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- dapagliflozin, SGLT2 inhibitors, type 2 diabetes, chronic kidney disease, data correction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
